Modulation of transforming growth factor-β (TGF-β) signaling by endogenous sphingolipid mediators

被引:55
|
作者
Sato, M
Markiewicz, M
Yamanaka, M
Bielawska, A
Mao, CG
Obeid, LM
Hannun, YA
Trojanowska, M
机构
[1] Med Univ S Carolina, Div Rheumatol & Immunol, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA
[3] Ralph H Johnson Vet Affairs Hosp, Div Gen Internal Med, Charleston, SC 29425 USA
关键词
D O I
10.1074/jbc.M211529200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Transforming growth factor-beta (TGF-beta) is a multifunctional growth factor that plays a critical role in tissue repair and fibrosis. Sphingolipid signaling has been shown to regulate a variety of cellular processes and has been implicated in collagen gene regulation. The present study was undertaken to determine whether endogenous sphingolipids are involved in the TGF-beta signaling pathway. TGF-beta treatment induced endogenous ceramide levels in a time-dependent manner within 5-15 min of cell stimulation. Using human fibroblasts transfected with a alpha2(l) collagen promoter/reporter gene construct (COL1A2), C.-ceramide (10 muM) exerted a stimulatory effect on basal and TGF-beta-induced activity of this promoter. Next, to define the effects of endogenous sphingolipids on TGF-beta signaling we employed ectopic expression of enzymes involved in sphingolipid metabolism. Sphingosine 1-phosphate phosphatase (YSR2) stimulated basal COL1A2 promoter activity and cooperated with TGF-beta in activation of this promoter. Furthermore, overexpression of YSR2 resulted in the pronounced increase of COL1A1 and COL1A2 mRNA levels. Conversely, overexpression of sphingosine kinase (SPHK1) inhibited basal and TGF-beta-stimulated COL1A2 promoter activity. These results suggest that endogenous ceramide, but not sphingosine or sphingosine 1-phosphate, is a positive regulator of collagen gene expression. Mechanistically, we demonstrate that Smad3 is a target of YSR2. TGF-beta-induced Smad3 phosphorylation was elevated in the presence of YSR2. Cotransfection of YSR2 with wild-type Smad3, but not with the phosphorylation-deficient mutant of Smad3 (Smad3A), resulted in a dramatic increase of COL1A2 promoter activity. In conclusion, this study demonstrates a direct role for the endogenous sphingolipid mediators in regulating the TGF-beta signaling pathway.
引用
收藏
页码:9276 / 9282
页数:7
相关论文
共 50 条
  • [31] Transforming growth factor-β1 (TGF-β1) signaling as a new pharmacological target against Aβ-induced neurodegeneration
    Caraci, F.
    Battaglia, G.
    Busceti, C.
    Biagioni, F.
    Mastroiacovo, F.
    Bosco, P.
    Drago, F.
    Nicoletti, F.
    Sortino, M. A.
    Copani, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S168 - S168
  • [32] Type III transforming growth factor-β (TGF-β) receptor mediates apoptosis in renal cell carcinoma independent of the canonical TGF-β signaling pathway
    Margulis, Vitally
    Maity, Tapati
    Zhang, Xiu-Ying
    Cooper, Simon J.
    Copland, John A.
    Wood, Christopher G.
    CLINICAL CANCER RESEARCH, 2008, 14 (18) : 5722 - 5730
  • [33] Identification of BAT3 as a novel functional interacting protein with transforming growth factor-β (TGF-β) receptor:: Role in TGF-β signaling.
    Kwak, JH
    Warywoda, M
    Choi, ME
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 15A - 15A
  • [34] Interaction of transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) in human glioma cells
    Janka Held-Feindt
    Björn Lütjohann
    Hendrik Ungefroren
    Hubertus M. Mehdorn
    Rolf Mentlein
    Journal of Neuro-Oncology, 2003, 63 : 117 - 127
  • [35] Transforming growth factor- (TGF-)-induced up-regulation of TGF- receptors at the cell surface amplifies the TGF- response
    Duan, Dana
    Derynck, Rik
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (21) : 8490 - 8504
  • [36] Interaction of transforming growth factor-β (TGF-β) and epidermal growth factor (EGF) in human glioma cells
    Held-Feindt, J
    Lütjohann, B
    Ungefroren, H
    Mehdorn, HM
    Mentlein, R
    JOURNAL OF NEURO-ONCOLOGY, 2003, 63 (02) : 117 - 127
  • [37] An engineered transforming growth factor β (TGF-β) monomer that functions as a dominant negative to block TGF-β signaling
    Kim, Sun Kyung
    Barron, Lindsey
    Hinck, Cynthia S.
    Petrunak, Elyse M.
    Cano, Kristin E.
    Thangirala, Avinash
    Iskra, Brian
    Brothers, Molly
    Vonberg, Machell
    Leal, Belinda
    Richter, Blair
    Kodali, Ravindra
    Taylor, Alexander B.
    Du, Shoucheng
    Barnes, Christopher O.
    Sulea, Traian
    Calero, Guillermo
    Hart, P. John
    Hart, Matthew J.
    Demeler, Borries
    Hinck, Andrew P.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2017, 292 (17) : 7173 - 7188
  • [38] Renal expression of fibrotic matrix proteins and of transforming growth factor-β (TGF-β) isoforms in TGF-β transgenic mice
    Mozes, MM
    Böttinger, EP
    Jacot, TA
    Kopp, JB
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1999, 10 (02): : 271 - 280
  • [39] Transforming growth factor-β (TGF-β) and vascular disease -: CARP as a putative TGF-β target gene in the vessel wall
    Topper, JN
    CIRCULATION RESEARCH, 2001, 88 (01) : 5 - 6
  • [40] Transforming growth factor-β gene silencing using adenovirus expressing TGF-β1 or TGF-β2 shRNA
    Oh, S.
    Kim, E.
    Kang, D.
    Kim, M.
    Kim, J-H
    Song, J. J.
    CANCER GENE THERAPY, 2013, 20 (02) : 94 - 100